SOTAC PHARMACEUTICALS
|
SOTAC PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 2.84 | 12.52 | -10.28 | 0.38 |
| CEPS(Rs) | 5.67 | 4.98 | 0.28 | 1.85 |
| DPS(Rs) | - | 2.00 | - | - |
| Book NAV/Share(Rs) | 12.41 | 28.79 | 10.84 | 13.29 |
| Tax Rate(%) | 41.78 | 38.68 | -15.02 | 75.49 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 9.44 | 8.44 | 2.98 | 6.53 |
| EBIT Margin(%) | 7.70 | 7.20 | -2.11 | 2.41 |
| Pre Tax Margin(%) | 5.07 | 6.42 | -4.21 | 1.25 |
| PAT Margin (%) | 2.95 | 3.94 | -4.84 | 0.31 |
| Cash Profit Margin (%) | 5.89 | 5.48 | 0.47 | 5.20 |
| Performance Ratios | ||||
| ROA(%) | 4.20 | 8.23 | -7.27 | 0.29 |
| ROE(%) | 27.53 | 63.16 | -85.23 | 2.86 |
| ROCE(%) | 21.50 | 31.31 | -5.71 | 4.18 |
| Asset Turnover(x) | 1.42 | 2.09 | 1.50 | 0.94 |
| Sales/Fixed Asset(x) | 3.34 | 4.12 | 2.39 | 1.52 |
| Working Capital/Sales(x) | 58.39 | -42.31 | -9.02 | -5.11 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.30 | 0.24 | 0.42 | 0.66 |
| Receivable days | 64.05 | 45.25 | 47.99 | 88.82 |
| Inventory Days | 44.84 | 25.51 | 26.72 | 29.65 |
| Payable days | 143.83 | 106.65 | 112.91 | 193.78 |
| Valuation Parameters | ||||
| PER(x) | - | - | - | - |
| PCE(x) | - | - | - | - |
| Price/Book(x) | - | - | - | - |
| Yield(%) | - | - | - | - |
| EV/Net Sales(x) | 0.26 | 0.13 | 0.39 | 0.54 |
| EV/Core EBITDA(x) | 2.66 | 1.51 | 12.26 | 7.33 |
| EV/EBIT(x) | 3.42 | 1.83 | -18.58 | 22.20 |
| EV/CE(x) | 0.28 | 0.27 | 0.55 | 0.50 |
| M Cap / Sales | - | - | - | - |
| Growth Ratio | ||||
| Net Sales Growth(%) | 5.92 | 49.77 | 70.76 | - |
| Core EBITDA Growth(%) | 19.95 | 309.00 | -25.23 | - |
| EBIT Growth(%) | 13.37 | 610.65 | -249.43 | - |
| PAT Growth(%) | -20.58 | 221.70 | -2,803.31 | - |
| EPS Growth(%) | -77.31 | 221.70 | -2,803.31 | - |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 2.21 | 1.12 | 6.87 | 4.40 |
| Current Ratio(x) | 1.03 | 0.94 | 0.76 | 0.71 |
| Quick Ratio(x) | 0.73 | 0.74 | 0.55 | 0.59 |
| Interest Cover(x) | 2.92 | 9.24 | -1.01 | 2.07 |
| Total Debt/Mcap(x) | - | - | - | - |
Compare Financial Ratios of peers of SOTAC PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SOTAC PHARMACEUTICALS | ₹137.2 Cr | -1.1% | 1.3% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹367,290.0 Cr | -0.9% | 0.9% | 62.6% | Stock Analytics | |
| CIPLA | ₹113,357.0 Cr | 3.5% | 4.2% | 51.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹111,134.0 Cr | 12.2% | 18% | 103.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹104,235.0 Cr | 0.8% | 5.6% | 19.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,001.5 Cr | -1% | -2.4% | 28.4% | Stock Analytics | |
SOTAC PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOTAC PHARMACEUTICALS | -1.1% |
1.3% |
|
| SENSEX | 1.7% |
1.5% |
18.7% |
You may also like the below Video Courses
